These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 12971971)

  • 1. Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B.
    Boni C; Penna A; Bertoletti A; Lamonaca V; Rapti I; Missale G; Pilli M; Urbani S; Cavalli A; Cerioni S; Panebianco R; Jenkins J; Ferrari C
    J Hepatol; 2003 Oct; 39(4):595-605. PubMed ID: 12971971
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiviral T-cell responses and therapy in chronic hepatitis B.
    Alatrakchi N; Koziel MJ
    J Hepatol; 2003 Oct; 39(4):631-4. PubMed ID: 12971976
    [No Abstract]   [Full Text] [Related]  

  • 3. Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy.
    Boni C; Penna A; Ogg GS; Bertoletti A; Pilli M; Cavallo C; Cavalli A; Urbani S; Boehme R; Panebianco R; Fiaccadori F; Ferrari C
    Hepatology; 2001 Apr; 33(4):963-71. PubMed ID: 11283861
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High frequency of functional anti-YMDD and -mutant cytotoxic T lymphocytes after in vitro expansion correlates with successful response to lamivudine therapy for chronic hepatitis B.
    Lin CL; Tsai SL; Lee TH; Chien RN; Liao SK; Liaw YF
    Gut; 2005 Jan; 54(1):152-61. PubMed ID: 15591521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of HBV-DNA fluctuations on virus-specific CD8+ T cells in HBeAg+ chronic hepatitis B patients treated with a steroid and lamivudine.
    Gotto J; Webster GJ; Brown D; Jenkins J; Dusheiko GM; Bertoletti A
    J Viral Hepat; 2006 Jun; 13(6):415-25. PubMed ID: 16842445
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lamivudine plus interleukin-12 combination therapy in chronic hepatitis B: antiviral and immunological activity.
    Rigopoulou EI; Suri D; Chokshi S; Mullerova I; Rice S; Tedder RS; Williams R; Naoumov NV
    Hepatology; 2005 Nov; 42(5):1028-36. PubMed ID: 16250037
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B.
    Boni C; Bertoletti A; Penna A; Cavalli A; Pilli M; Urbani S; Scognamiglio P; Boehme R; Panebianco R; Fiaccadori F; Ferrari C
    J Clin Invest; 1998 Sep; 102(5):968-75. PubMed ID: 9727065
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Programmed death 1 expression during antiviral treatment of chronic hepatitis B: Impact of hepatitis B e-antigen seroconversion.
    Evans A; Riva A; Cooksley H; Phillips S; Puranik S; Nathwani A; Brett S; Chokshi S; Naoumov NV
    Hepatology; 2008 Sep; 48(3):759-69. PubMed ID: 18697210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and immunological efficacy of intradermal vaccine plus lamivudine with or without interleukin-2 in patients with chronic hepatitis B.
    Dahmen A; Herzog-Hauff S; Böcher WO; Galle PR; Löhr HF
    J Med Virol; 2002 Apr; 66(4):452-60. PubMed ID: 11857521
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues.
    Boni C; Laccabue D; Lampertico P; Giuberti T; Viganò M; Schivazappa S; Alfieri A; Pesci M; Gaeta GB; Brancaccio G; Colombo M; Missale G; Ferrari C
    Gastroenterology; 2012 Oct; 143(4):963-73.e9. PubMed ID: 22796241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [HBV-specific CD8+ T cells for sustained HBeAg seroconversion after lamivudine therapy].
    Lee CK; Han KH; Suh JH; Cho YS; Won SY; Chon CY; Moon YM; Park IS
    Korean J Hepatol; 2005 Mar; 11(1):34-42. PubMed ID: 15788883
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intrahepatic CD8+ T-lymphocyte response is important for therapy-induced viral clearance in chronic hepatitis B infection.
    Tang TJ; Kwekkeboom J; Mancham S; Binda RS; de Man RA; Schalm SW; Kusters JG; Janssen HL
    J Hepatol; 2005 Jul; 43(1):45-52. PubMed ID: 15893402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tracking the source of the hepatitis B virus-specific CD8 T cells during lamivudine treatment.
    Malacarne F; Webster GJ; Reignat S; Gotto J; Behboudi S; Burroughs AK; Dusheiko GM; Williams R; Bertoletti A
    J Infect Dis; 2003 Feb; 187(4):679-82. PubMed ID: 12599086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intrahepatic CD8 T-lymphocytes and HBV core expression in relation to response to antiviral therapy for chronic hepatitis B patients.
    Tang TJ; de Man RA; Kusters JG; Kwekkeboom J; Hop WC; van der Molen RG; Schalm SW; Janssen HL
    J Med Virol; 2004 Feb; 72(2):215-22. PubMed ID: 14695662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatitis B virus-specific T-cell proliferation and cytokine secretion in chronic hepatitis B e antibody-positive patients treated with ribavirin and interferon alpha.
    Rico MA; Quiroga JA; Subirá D; Castañón S; Esteban JM; Pardo M; Carreño V
    Hepatology; 2001 Jan; 33(1):295-300. PubMed ID: 11124848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo immunization by vaccine therapy following virus suppression by lamivudine: a novel approach for treating patients with chronic hepatitis B.
    Horiike N; Fazle Akbar SM; Michitaka K; Joukou K; Yamamoto K; Kojima N; Hiasa Y; Abe M; Onji M
    J Clin Virol; 2005 Feb; 32(2):156-61. PubMed ID: 15653419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced hepatitis B virus (HBV)-specific CD4+ T-cell responses in human immunodeficiency virus type 1-HBV-coinfected individuals receiving HBV-active antiretroviral therapy.
    Chang JJ; Wightman F; Bartholomeusz A; Ayres A; Kent SJ; Sasadeusz J; Lewin SR
    J Virol; 2005 Mar; 79(5):3038-51. PubMed ID: 15709024
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin-35 Suppresses Antiviral Immune Response in Chronic Hepatitis B Virus Infection.
    Shao X; Ma J; Jia S; Yang L; Wang W; Jin Z
    Front Cell Infect Microbiol; 2017; 7():472. PubMed ID: 29181338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of early viral kinetics on T-cell reactivity during antiviral therapy in chronic hepatitis B.
    Lau GK; Cooksley H; Ribeiro RM; Powers KA; Shudo E; Bowden S; Hui CK; Anderson J; Sorbel J; Mondou E; Rousseau F; Lewin S; Perelson AS; Locornini S; Naoumov NV
    Antivir Ther; 2007; 12(5):705-18. PubMed ID: 17713154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A multi-center open study to determine the effect of lamivudine on HBV DNA clearance and to assess the safety of the regimen in patients with chronic hepatitis B infection.
    Mazur W; Król F; Cianciara J; Nazzal K; Gładysz A; Juszczyk J; Bolewska B; Adamek J; Czajka B; Swietek K; Kryczka W; Gonciarz Z
    Med Sci Monit; 2002 Apr; 8(4):CR257-62. PubMed ID: 11951067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.